Biodexa Pharmaceuticals PLC (Form 6-K)

Key update for November 2025:

• Clinical Trial Milestone: Received approval of a Clinical Trial Application (CTA) from the European Medicines Agency (EMA).
• Trial Details: The approval greenlights the pivotal Phase 3 Serenta clinical trial utilizing eRapa.
• Indication: Treatment for patients with familial adenomatous polyposis (FAP).
• Jurisdiction: Trial will proceed across European sites, starting with Denmark, Germany, the Netherlands, and Spain, with Italy expected to join.
• Management: Signed by St